Evidence map›Paper›PMID 35086043›Full record

ArticleJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology2022

Detection of SARS-CoV-2 variants by Abbott molecular, antigen, and serological tests.

Mary A Rodgers, Ana Olivo, Barbara J Harris, Chris Lark, Xinxin Luo, Michael G Berg, Todd V Meyer, Aurash Mohaimani, Gregory S Orf, Yitz Goldstein and 19 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. A Targeted LC-MRMMolecular & cellular proteomics : MCP · 2024
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. The Abbott Pandemic Defense Coalition: a unique multisector approach adds to global pandemic preparedness efforts.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 8 institutions in 4 countries.

Mary A RodgersAbbott Diagnostics, Abbott Park, IL, USA. Electronic address: mary.rodgers@abbott.com.
Ana OlivoAbbott Diagnostics, Abbott Park, IL, USA.
Barbara J HarrisAbbott Diagnostics, Abbott Park, IL, USA.
Chris LarkAbbott Diagnostics, Abbott Park, IL, USA.
Xinxin LuoAbbott Diagnostics, Abbott Park, IL, USA.
Michael G BergAbbott Diagnostics, Abbott Park, IL, USA.
Todd V MeyerAbbott Diagnostics, Abbott Park, IL, USA.
Aurash MohaimaniAbbott Diagnostics, Abbott Park, IL, USA.
Gregory S OrfAbbott Diagnostics, Abbott Park, IL, USA.
Yitz GoldsteinMontefiore Medical Center, NY, USA.
Amy S FoxMontefiore Medical Center, NY, USA.
Julie HirschhornMedical University of South Carolina, SC, USA.
William B GlenMedical University of South Carolina, SC, USA.
Frederick NolteMedical University of South Carolina, SC, USA.
Alan LandayRush University Medical Center, IL, USA.
Cheryl JenningsRush University Medical Center, IL, USA.
James MoyRush University Medical Center, IL, USA.
Venice ServellitaUniversity of California San Francisco, CA, USA.
Charles ChiuUniversity of California San Francisco, CA, USA.
Rahul BatraGuy's and St Thomas' NHS Foundation, London, UK.
Luke B SnellGuy's and St Thomas' NHS Foundation, London, UK.
Gaia NebbiaGuy's and St Thomas' NHS Foundation, London, UK.
Sam DouthwaiteGuy's and St Thomas' NHS Foundation, London, UK.
Amilcar TanuriUniversidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Lavanya SinghUniversity of KwaZulu-Natal, Durban, South Africa.
Tulio de OliveiraUniversity of KwaZulu-Natal, Durban, South Africa.
Ambroise AhouidiInstitute for Health Research Epidemiological Surveillance and Training, Dakar, Senegal.
Souleymane MboupInstitute for Health Research Epidemiological Surveillance and Training, Dakar, Senegal.
Gavin A ClohertyAbbott Diagnostics, Abbott Park, IL, USA.
Abbott Fund · USGuy's and St Thomas' NHS Foundation Trust · GBMedical University of South Carolina · USRush University Medical Center · USMontefiore Medical Center · USUniversity of California, San Francisco · USUniversity of KwaZulu-Natal · ZAUniversidade Federal do Rio de Janeiro · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundViral diversity presents an ongoing challenge for diagnostic tests, which need to accurately detect all circulating variants. The Abbott Global Surveillance program monitors severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants and their impact on diagnostic test performance.

objectivesTo evaluate the capacity of Abbott molecular, antigen, and serologic assays to detect circulating SARS-CoV-2 variants, including all current variants of concern (VOC): B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma) and B.1.617.2 (delta). STUDY

designDilutions of variant virus cultures (B.1.1.7, B.1.351, B.1.429, B.1.526.1, B.1.526.2, B.1.617.1, B.1.617.2, P.1, R.1 and control isolate WA1) and a panel of N = 248 clinical samples from patients with sequence confirmed variant infections (B.1.1.7, B.1.351, B.1.427, B.1.429, B.1.526, B.1.526.1, B.1.526.2, P.1, P.2, R.1) were evaluated on at least one assay: Abbott ID NOW COVID-19, m2000 RealTime SARS-CoV-2, Alinity m SARS-CoV-2, and Alinity m Resp-4-Plex molecular assays; the BinaxNOW COVID-19 Ag Card and Panbio COVID-19 Ag Rapid Test Device; and the ARCHITECT/Alinity i SARS-CoV-2 IgG and AdviseDx IgM assays, Panbio COVID-19 IgG assay, and ARCHITECT/Alinity i AdviseDx SARS-CoV-2 IgG II assay.

resultsConsistent with in silico predictions, each molecular and antigen assay detected VOC virus cultures with equivalent sensitivity to the WA1 control strain. Notably, 100% of all tested variant patient specimens were detected by molecular assays (N = 197 m2000, N = 88 Alinity m, N = 99 ID NOW), and lateral flow assays had a sensitivity of >94% for specimens with genome equivalents (GE) per device above 4 log (85/88, Panbio; 54/57 Binax). Furthermore, Abbott antibody assays detected IgG and IgM in 94-100% of sera from immune competent B.1.1.7 patients 15-26 days after symptom onset.

conclusionsThese data confirm variant detection for 11 SARS-CoV-2 assays, which is consistent with each assay target region being highly conserved. Importantly, alpha, beta, gamma, and delta VOCs were detected by molecular and antigen assays, indicating that these tests may be suitable for widescale use where VOCs predominate.

Indexed as

COVID-19SARS-CoV-2Antibodies, ViralHumansSensitivity and SpecificitySerologic TestsAntibodies, ViralAntibody assaysMolecular diagnosticsRapid antigen testsSARS-CoV-2Variant of concern

Identifiers

PMID35086043
PMCPMC8770247
OpenAlexW4226284222

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.